期刊
MOLECULAR CANCER THERAPEUTICS
卷 7, 期 10, 页码 3420-3428出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-08-0629
关键词
-
类别
资金
- Cure for Life Foundation
- Andrew Olle Memorial Trust
- Sydney Neuro-Oncology Group
Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D-2 (PGD(2)) synthase (PGDS), the main arachiclonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival. In vitro, the addition of the main PGDS metabolite, PGD(2), to A172 glioblastoma cells devoid of PGDS resulted in antiproliferative activity and cell death. In vitro PGD(2) substitution also enhanced the efficacy of cyclo-oxygenase-2 inhibitors. This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据